Many physicians and nurse practitioners are drawn to aesthetic medicine as a side hustle—but the reality involves more than a weekend course and a few injection sessions. This guide breaks down the true time commitment, startup costs, and income potential so you can decide if the trade-offs are right for you.
Many physicians and nurse practitioners are drawn to aesthetic medicine as a side hustle—but the reality involves more than a weekend course and a few injection sessions. This guide breaks down the true time commitment, startup costs, and income potential so you can decide if the trade-offs are right for you.
This article breaks down Botox pricing 2026 benchmarks so new aesthetic providers can avoid undercharging. Learn how to use memberships and value-based pricing to build a profitable injectable practice.
Ultrasound skin tightening is becoming a go‑to option in 2026 for patients who want better skin architecture without looking overfilled. This article explains how ultrasound skin tightening fits into GLP‑1 weight-loss plans, wedding timelines, and Q2 device strategy.
March 2026 brought meaningful advances in aesthetic medicine, from new FDA-approved options for managing GLP-1-related facial volume loss to strengthening clinical evidence for polynucleotide and exosome therapies. This roundup covers the developments most relevant to certified aesthetic providers, including new consensus guidance, shifting patient demographics, and an evolving regulatory landscape.
Two oral GLP-1 medications for obesity are now FDA-approved — Eli Lilly’s Foundayo (orforglipron) and Novo Nordisk’s Wegovy pill (semaglutide 25 mg) — and they are meaningfully different. This clinical comparison breaks down the trial data, dosing requirements, and pricing so providers can have informed conversations with patients.
Insurance-based practice has become one of the leading structural drivers of physician burnout — but the solution is not a wellness seminar. For a growing number of physicians, cash-based aesthetic medicine is the deliberate exit strategy that removes the administrative burden and puts them back in control of their time and income.
The retatrutide warning is one every GLP-1 provider needs to hear before a patient asks about it. This investigational drug is not FDA-approved, cannot legally be compounded, and sourcing it could leave your practice without malpractice coverage.
The FDA has approved Wegovy 7.2 mg, tripling the previous maximum dose of high-dose semaglutide and raising important new questions about patient selection, safety, and the role of lifestyle support. Here is what medical weight loss providers need to know before this higher-dose option reaches U.S. pharmacies in April 2026.
Temple hollowing has become a hallmark of “Ozempic face” in GLP‑1 patients, often making people look older even as their health improves. This article explains how Restylane Contour’s new FDA approval for temple hollowing fits into safe, staged treatment planning for this rapidly growing patient group.
Terms and conditions apply. Offer expires October 31.